Monte Rosa Therapeutics Presents Preclinical Data At EULAR 2024 Regarding MRT-6160 For Treatment Of Rheumatoid Arthritis

6/14/24 8:46:08 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GLUE alert in real time by email

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis

Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025

Get the next $GLUE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GLUE

Date	Price Target	Rating	Analyst
2/15/2024	$11.00	Outperform	Wedbush
1/3/2023	$18.00	Equal Weight → Overweight	Wells Fargo
10/13/2022	$22.00	Buy	UBS
8/15/2022	$20.00	Buy	Jefferies
4/28/2022	$19.00	Neutral	Credit Suisse
2/10/2022	$19.00	Equal-Weight	Wells Fargo
10/14/2021	$20.00	Mkt Perform	SVB Leerink
7/19/2021	$30.00	Buy	Guggenheim

More analyst ratings

$GLUE
Press Releases

Fastest customizable press release news feed in the world

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 4:00 p.m. GMT. A webcast of the fireside chat will be accessible via the "Events" section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highl
11/13/24 7:00:00 AM ET
$GLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M upfront payment, eligible for up to $2.1B milestones and U.S. P&L share MRT-6160 Phase 1 SAD/MAD study ongoing with initial clinical data expected by Q1 2025 Phase 1/2 study of MRT-2359, in development for MYC-driven solid tumors, ongoing with updated clinical results anticipated by year-end MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Strengthened cash position, including anticipated $150 mi
11/7/24 7:00:00 AM ET
$GLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U.S. profit and loss share, and tiered royalties on ex-U.S. net sales BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 MGDs, including MRT-6160. MRT-6160 is currently in an ongoing Phase 1, singl
10/28/24 7:00:00 AM ET
$GLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$GLUE
Leadership Updates

Live Leadership Updates

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. "Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we're delighted to have him on our team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Tony's experience developing multiple first-in-class therapeutics for the treatment of
7/26/23 7:30:00 AM ET
$GLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Directors, bringing his extensive experience as a life sciences leader to the team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Having served as the CEO of two clinical-stage companies, Jan has demon
3/23/23 7:30:00 AM ET
$GLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm of study expected in second half of 2023MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionNomination of multiple development candidates anticipated in 2023Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025 BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, to
3/16/23 7:30:00 AM ET
$GLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Monte Rosa Therapeutics Presents Preclinical Data At EULAR 2024 Regarding MRT-6160 For Treatment Of Rheumatoid Arthritis

Chat with this insight

Recent Analyst Ratings for
$GLUE

$GLUE
Financials

Live finance-specific insights

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

$GLUE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wedbush initiated coverage on Monte Rosa Therapeutics with a new price target

Monte Rosa Therapeutics upgraded by Wells Fargo with a new price target

UBS initiated coverage on Monte Rosa Therapeutics with a new price target

$GLUE
Press Releases

Fastest customizable press release news feed in the world

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

$GLUE
Leadership Updates

Live Leadership Updates

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

$GLUE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Monte Rosa Therapeutics Inc.

$GLUE
SEC Filings

SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Monte Rosa Therapeutics Inc.

$GLUE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Versant Venture Capital Vi, L.P. sold $1,491,041 worth of shares (157,895 units at $9.44), disposed of 1,435,402 shares and acquired 48,945 shares (SEC Form 4)

Large owner Versant Venture Capital Vi, L.P. sold $7,395,203 worth of shares (1,132,566 units at $6.53) (SEC Form 4)

Large owner Versant Venture Capital Vi, L.P. sold $3,404,791 worth of shares (567,213 units at $6.00) (SEC Form 4)

$GLUE
Market Insights

Live Market Insights

Watching Monte Rosa Therapeutics, Zura Bio; Shares See Volume Amid TipRanks Issues Report Mentioning The Two Stocks

Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target

Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases

Monte Rosa Therapeutics Presents Preclinical Data At EULAR 2024 Regarding MRT-6160 For Treatment Of Rheumatoid Arthritis

Chat with this insight

Recent Analyst Ratings for $GLUE

$GLUE Financials

Live finance-specific insights

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

$GLUE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wedbush initiated coverage on Monte Rosa Therapeutics with a new price target

Monte Rosa Therapeutics upgraded by Wells Fargo with a new price target

UBS initiated coverage on Monte Rosa Therapeutics with a new price target

$GLUE Press Releases

Fastest customizable press release news feed in the world

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

$GLUE Leadership Updates

Live Leadership Updates

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

$GLUE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Monte Rosa Therapeutics Inc.

Amendment: SEC Form SC 13D/A filed by Monte Rosa Therapeutics Inc.

$GLUE SEC Filings

SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Monte Rosa Therapeutics Inc.

$GLUE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Versant Venture Capital Vi, L.P. sold $1,491,041 worth of shares (157,895 units at $9.44), disposed of 1,435,402 shares and acquired 48,945 shares (SEC Form 4)

Large owner Versant Venture Capital Vi, L.P. sold $7,395,203 worth of shares (1,132,566 units at $6.53) (SEC Form 4)

Large owner Versant Venture Capital Vi, L.P. sold $3,404,791 worth of shares (567,213 units at $6.00) (SEC Form 4)

$GLUE Market Insights

Live Market Insights

Watching Monte Rosa Therapeutics, Zura Bio; Shares See Volume Amid TipRanks Issues Report Mentioning The Two Stocks

Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target

Monte Rosa Therapeutics Announced Progress Updates For Its Two Lead Programs, MRT-2359, An MGD Being Developed For MYC-Driven Solid Tumors, And MRT-6160, A VAV1-directed MGD In Development For Systemic And Neurological Autoimmune Diseases

Recent Analyst Ratings for
$GLUE

$GLUE
Financials

$GLUE
Analyst Ratings

$GLUE
Press Releases

$GLUE
Leadership Updates

$GLUE
Large Ownership Changes

$GLUE
SEC Filings

$GLUE
Insider Trading

$GLUE
Market Insights